Take a fresh look at your lifestyle.

2seventy bio to lay off 40% of workforce

Investing.com - Financial Markets Worldwide


All Instrument Types

  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Published Sep 12, 2023 07:39AM ET Updated Sep 12, 2023 07:45AM ET

2seventy bio to lay off 40% of workforce © Reuters.

(Reuters) – 2seventy bio said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm’s cancer cell therapy Abecma.

The company will save about $130 million in 2024-25 as it eliminates 176 roles.

2seventy bio said it expects a decline in Abecma sales in the third quarter and U.S. revenue for the therapy in 2023 could be lower than the $470-$570 million range it previously projected.

The company added that CEO Nick Leschly will step down and transition to the role of chairman.

2seventy bio to lay off 40% of workforce

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More